Melanoma Fact Sheet

The Disease

- Melanoma, the most serious form of skin cancer, is characterized by the uncontrolled growth of pigment cells (melanocytes) that produce skin color.\(^1\)

- Melanoma usually develops in the skin (cutaneous melanoma), but may also occur in the:
  - Eyes (ocular or intraocular melanoma)
  - Membrane covering the brain and spinal cord (meninges)
  - Digestive tract
  - Lymph nodes
  - Other areas where melanocytes are found

- Most melanomas (more than 70 percent) begin in or near an existing mole or dark spot on the skin. Some "birthmarks" (congenital moles) can also develop into melanomas.\(^1\)

Key Statistics

- Cancer of the skin (nonmelanoma and melanoma skin cancers combined) is the most common type of cancer, accounting for more than 50 percent of all cancers.\(^3\)

- In some parts of the world, especially among Western countries, melanoma is becoming more common every year. In the United States, for example, the percentage of people who develop melanoma has more than doubled in the past 30 years.\(^2\)

- Melanoma accounts for about four percent of skin cancer cases but causes about 79 percent of skin cancer deaths.\(^3\)

- It is estimated that about 55,000 new melanomas will be diagnosed in the United States during 2004.\(^2,3\)

- Nearly 8,000 people in the United States are expected to die of melanoma during 2004.\(^2,3\)

- About 132,000 people worldwide are diagnosed with melanoma each year, and more than 37,000 of them die from the disease annually.\(^4\)
• About five percent of patients with melanoma will develop metastases from the original tumor.\(^5\)

• There has been a steady increase in melanoma incidence worldwide, primarily attributed to increased sun exposure.\(^4\)

**Risk Factors & Symptoms** \(^1,2\)

• Risk factors for melanoma include:
  
  - Dysplastic nevi (atypical mole)
  - Fair skin
  - Freckles
  - Family or personal history
  - Weakened immune system
  - Too much exposure to ultraviolet rays, radiation and sunburn
  - Age (approximately half of all melanomas occur in people over the age of 50)
  - Gender (men are more likely to develop melanoma than women)

• The first sign of melanoma is often a change in the size, shape, color, or feel of an existing mole.

• Most melanomas have a black or blue-black area.

• Melanoma also may appear as a new, black, abnormal or "ugly-looking" mole.

**Treatment**

• Melanoma can be treated successfully if detected at an early stage. If not, it may spread to other parts of the body and result in death.\(^2\)

• Treatment is based on the age and general health of the patient as well as on the stage of the disease.\(^5\)

• Surgery is currently the first line of treatment for any stage of melanoma. In later stages, surgery is generally followed by chemotherapy, radiation therapy or immunotherapy (Interferon and Interleukin).\(^5\)

• Melanoma that has spread to other parts of the body (metastatic) is rarely curable with standard therapy.\(^2\)

• Only 13 percent of patients with stage IV and 44 percent with stage III, are alive five years after the diagnosis.\(^6,7\)
Forward Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including its Form 20-F). Bayer assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Leverkusen, June 7, 2004

Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ute Krippendorf (+49-214-30-33021)
Ilia Kürten (+49-214-30-35426)
Judith Nestmann (+49-214-30-66836)

References:
1-American Melanoma Foundation;
2-National Cancer Institute;
3-American Cancer Society;
4-WHO;
5-Melanoma.com;
6-Oncolink.com;